BioCentury
ARTICLE | Finance

DMD rollercoaster

Santhera's wild ride on DMD data for Catena; CHMP backing for PTC's Translarna

May 26, 2014 7:00 AM UTC

Santhera Pharmaceuticals Holding AG (SIX:SANN) has had a wild month in which developments in the DMD space have driven up the stock nearly 600%.

The ride started on May 12, when the company said its Catena idebenone met the primary endpoint in the Phase III DELOS trial to treat Duchenne muscular dystrophy (DMD). The following day, Santhera was up CHF0.69 (18%) to CHF4.44...